bioAffinity Technologies Inc. is an innovative biotech company focused on the development and commercialization of non-invasive, early-stage cervical and lung cancer detection tests. Headquartered in San Antonio, Texas, bioAffinity is passionately committed to the creation of cutting edge, patient-friendly, and potentially life-saving diagnostic and screening technologies based on advanced, proprietary biomarker discovery.
The company was co-founded in 2007 by Maria Zannes, an accomplished healthcare executive, and Dr. Vivienne Rebel, an acclaimed scientist and hematologist. Together, they set out to tackle the medical industry's most pressing necessity: the early detection of cancer, which can dramatically improve patients' treatment outcomes and survival rates.
A major breakthrough in their work is the CyPath® technology, a ground-breaking platform that identifies and isolates cancer-associated molecular biomarkers present in biofluids, like blood and sputum. This patented technology allows for the detection of lung and cervical cancer in the earliest stages, offering hope for better prognosis and more effective treatments.
bioAffinity Technologies’ paramount product, the CyPath® Lung, is a non-invasive diagnostic test that identifies lung cancer in its earliest stages, when the disease is most treatable and survival rates highest. The CyPath® Lung test utilizes the patient's sputum sample to detect lung cancer with unique accuracy, thus providing an alternative to traditional invasive diagnostic procedures.
The company has also developed the CyPath® Cervical diagnostic test, utilizing vaginal fluid to detect harmful cells and early signs of cervical cancer. The company's advanced diagnostic solutions have the potential to greatly impact cancer survival rates and decrease the immense burdens of cost and patient suffering worldwide.
bioAffinity Technologies Inc. has a strong leadership team led by the CEO, Maria Zannes, who brings over 30 years of healthcare, management, and legal experience to the company. The team's collective experience and passion for innovating potentially life-saving technologies reflects in the company's commitment to clinical excellence and ground breaking research.
To date, the company has received significant academic and industry validation for its innovative diagnostic methods, which are a testament to the transformative potential of bioAffinity's work. The company operates with an unwavering commitment to scientific advancement and is continuing its diligent work in the field of cancer diagnostics, with the aim to save lives globally.